Incyte/$INCY
Incyte shares rise after Q3 revenue beat expectations and the company raised FY26 sales guidance.
21 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- Ticker
- $INCY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,844
- Headquarters
- Wilmington, United States
- Website
- www.incyte.com
Incyte Metrics
BasicAdvanced
$25B
61.93
$1.94
0.74
-
Price and volume
Market cap
$25B
Beta
0.74
52-week high
$132.60
52-week low
$89.25
Average daily volume
1.8M
Financial strength
Current ratio
3.915
Quick ratio
3.349
Long term debt to equity
0.005
Total debt to equity
0.006
Interest coverage (TTM)
828.46%
Profitability
EBITDA (TTM)
2,035.372
Gross margin (TTM)
55.98%
Net profit margin (TTM)
6.71%
Operating margin (TTM)
32.22%
Effective tax rate (TTM)
49.33%
Revenue per employee (TTM)
$2,110,000
Management effectiveness
Return on assets (TTM)
17.78%
Return on equity (TTM)
7.84%
Valuation
Price to earnings (TTM)
61.928
Price to revenue (TTM)
4.008
Price to book
4.35
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
35.434
Free cash flow yield (TTM)
2.82%
Free cash flow per share (TTM)
3.398
Growth
Revenue change (TTM)
24.88%
Earnings per share change (TTM)
-67.07%
3-year revenue growth (CAGR)
18.54%
10-year revenue growth (CAGR)
19.37%
3-year earnings per share growth (CAGR)
1.07%
10-year earnings per share growth (CAGR)
10.08%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Analyst projections of the future price of Incyte stock.
Bulls say / Bears say
Underlying net sales rose 17% in the second quarter, excluding a one-off accounting benefit, and Incyte raised its 2026 sales guidance. Growth across Opzelura and newer oncology products is helping reduce reliance on Jakafi. (Financial Times)
The FDA approved Jakafi XR in May for several blood-cancer and graft-versus-host disease uses. The extended-release version could help broaden the established franchise as demand for Jakafi continues to grow. (Financial Times)
Incyte’s partner Mirum won FDA approval for Atebrioz in fibrodysplasia ossificans progressiva, giving the company exposure to a newly approved rare-disease treatment. In the pivotal study, new bone-lesion volume fell by 3.2 cubic centimetres on treatment while it rose by 24.6 cubic centimetres on placebo. (Financial Times)
Jakafi remains Incyte’s largest-selling medicine, and its patent protection is expected to start waning around 2028. The company’s costly Vega acquisition is intended to build new revenue ahead of that looming loss of exclusivity. (Reuters)
Opzelura’s reported sales jumped 173% in the second quarter, but $246 million came from a one-off reversal of accrued liabilities. Sales excluding that benefit were $204 million, so the headline growth rate overstates the underlying commercial momentum. (Financial Times)
The proposed Vega purchase requires $1.25 billion in cash upfront and up to $750 million more in milestones. Incyte also raised its 2026 operating-expense outlook, including an expected $1.27 billion research charge tied to the deal, creating a substantial near-term earnings burden before the candidate is proven commercially. (Reuters, Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Incyte News
AllArticlesVideos
Funds containing Incyte
AllUSDEURGBP
Fund name | Fund size | $INCY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.51% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.51% |
iShares Ageing Population$AGED | $953M | 0.55% |
iShares Ageing Population€AGED | $903M | 0.55% |
iShares Ageing Population£AGES | $953M | 0.55% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.